Lupin enters into pact with Biomm
Source: IRIS | 06 Dec, 2021, 07.12PM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 Lupin, one of the leading pharmaceutical companies in India, have entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil. Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.
Pegfilgrastim is indicated to reduce the duration of neutropenia and the Incidence of febrile neutropenia in patients receiving chemotherapy.
Shares of the company declined Rs 15.15, or 1.74%, to settle at Rs 857.95. The total volume of shares traded was 55,560 at the BSE (Monday).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
